Skip to content

US · POM · MEDICAL - PHARMACEUTICALS

POMDOCTOR Ltd (POM) intrinsic value and stock valuation

$1.70as of 2026-11-21 · Mkt cap 4.74M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

POMDOCTOR Ltd DCF and intrinsic value

InvestorsCraft values POM with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from POM’s statements →

POMDOCTOR Ltd Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Pharmaceuticals Guangzhou, GD 510000 7lk.com

How the business is doing

Fiscal 2021–2025, USD

Revenue
$399.9M
20212025
Net income
-$-212.58M
20212025
Free cash flow
-$-149.49M
20212025
Total equity
-$-481.3M
20212025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2021–2025, USD
20252024202320222021
Revenue$399.9M$342.6M$304.9M$245.2M$215.4M
Operating income-$-116.37M-$-25.79M-$-22.25M-$-3.59M-$-79.67M
Net income-$-212.58M-$-143.36M-$-145.39M-$-125.51M-$-188.4M
EPSd-$-3.66M-$-21.79M-$-22.1M-$-19.07M-$-28.63M
Operating cash flow-$-148.48M-$-16.13M-$-45.8M-$-22.02M-$-15.68M
Capital expenditure-$-1.01M-$-40K-$-110K$0.00$0.00
Free cash flow-$-149.49M-$-16.17M-$-45.91M-$-22.02M-$-15.68M
Total assets$107.6M$46.2M$66.3M$48.6M$19.3M
Total debt$454.9M$441.1M$413.3M$361.2M$341.3M
Net debt$445.4M$433.5M$406.6M$358.8M$339.1M
Total equity-$-481.3M-$-2.09B-$-1.96B-$-1.9B-$-1.78B
Cash and short-term investments$9.58M$7.65M$6.72M$2.49M$2.17M
Income statement
20252024202320222021
Revenue$399.9M$342.6M$304.9M$245.2M$215.4M
Cost of revenue$347.6M$294.9M$266.1M$190.4M$162.9M
Gross profit$52.3M$47.7M$38.7M$54.9M$52.5M
Research and development expenses$12.9M$3M$3.37M$3.59M$4.28M
Selling, general and administrative expenses$155.9M$68.2M$56M$54.9M$103M
Other expenses-$-150K$2.24M$1.61M$0.00$24.9M
Operating expenses$168.7M$73.5M$61M$58.5M$132.2M
Cost and expenses$516.3M$368.4M$327.1M$248.8M$295.1M
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$12.9M$13M$13.9M$16M$16.3M
Depreciation and amortization$150K$130K$110K$0.00$21.3M
Ebitda-$-117.9M-$-24.27M-$-22.99M-$-3.81M-$-58.58M
Operating income-$-116.37M-$-25.79M-$-22.25M-$-3.59M-$-79.67M
Total other income/expenses, net-$-14.56M-$-11.57M-$-14.7M-$-16.24M-$-16.51M
Income before tax-$-130.93M-$-37.37M-$-36.95M-$-19.83M-$-96.18M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-212.58M-$-143.36M-$-145.39M-$-125.51M-$-188.4M
Weighted average shares outstanding$58.1M$6.58M$6.58M$6.58M$6.58M
Weighted average diluted shares outstanding$58.1M$6.58M$6.58M$6.58M$6.58M
Balance sheet
20252024202320222021
Cash and short-term investments$9.58M$7.65M$6.72M$2.49M$2.17M
Net receivables$24.8M$15M$32.4M$27.3M$740K
Inventory$8.28M$9.17M$12.7M$8.2M$8.12M
Total current assets$105M$37.5M$59.4M$47.7M$18.4M
Property, plant and equipment, net$1.25M$460K$600K$0.00$0.00
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$500K$500K
Total non-current assets$2.59M$8.73M$6.89M$880K$880K
Total assets$107.6M$46.2M$66.3M$48.6M$19.3M
Accounts payable$44.8M$25.4M$41.7M$43.4M$30.4M
Short-term debt$84.3M$74.3M$56.7M$30.9M$25.8M
Deferred revenue$1.59M$1.76M$1.24M$2.73M$1.46M
Total current liabilities$218.2M$179.2M$172M$143.6M$109.4M
Long-term debt$370.7M$366.8M$356.6M$330.4M$315.5M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$370.7M$1.96B$1.86B$1.8B$1.69B
Capital lease obligations$2.84M$3.06M$2.48M$12.9M$5.38M
Total liabilities$588.9M$2.14B$2.03B$1.95B$1.8B
Common stock$20K$0.00$0.00$0.00$0.00
Retained earnings-$-2.48B-$-2.26B-$-2.12B-$-1.97B-$-1.85B
Accumulated other comprehensive income (loss)-$-1.75M-$-10K$0.00$0.00$0.00
Total equity-$-481.3M-$-2.09B-$-1.96B-$-1.9B-$-1.78B
Total investments$0.00$0.00$0.00$500K$500K
Total debt$454.9M$441.1M$413.3M$361.2M$341.3M
Net debt$445.4M$433.5M$406.6M$358.8M$339.1M
Cash flow statement
20252024202320222021
Net income-$-130.93M-$-37.37M-$-36.95M-$-19.83M-$-96.18M
Depreciation and amortization$150K$130K$110K$0.00$21.3M
Stock-based compensation$16.4M$0.00$0.00$0.00$0.00
Change in working capital-$-37.87M$17.5M-$-12.56M-$-1.41M$35.1M
Accounts receivable-$-66.44M$16.5M-$-4.45M-$-26.75M-$-920K
Inventory-$-1M$3.03M-$-5M-$-80K-$-1.59M
Accounts payable$19.5M-$-16.34M-$-1.66M$12.9M$5.43M
Net cash provided by operating activities-$-148.48M-$-16.13M-$-45.8M-$-22.02M-$-15.68M
Investments in property, plant and equipment-$-1.01M-$-40K-$-110K$0.00$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-1.61M-$-30K-$-110K$0.00-$-500K
Common stock issued$163.9M$0.00$0.00$0.00$0.00
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$153.9M$17M$50.1M$22.5M$5.44M
Net change in cash$1.93M$850K$4.16M$470K-$-10.74M
Cash at end of period$9.58M$7.65M$6.81M$2.65M$2.17M
Operating cash flow-$-148.48M-$-16.13M-$-45.8M-$-22.02M-$-15.68M
Capital expenditure-$-1.01M-$-40K-$-110K$0.00$0.00
Free cash flow-$-149.49M-$-16.17M-$-45.91M-$-22.02M-$-15.68M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About POMDOCTOR Ltd

        Pomdoctor Limited, operating through its various divisions, runs an e-commerce platform for the direct sale of pharmaceutical products to consumers. The company is actively developing an online healthcare services platform specifically designed for managing long-term illnesses within the Chinese market. Its primary emphasis is on chronic disease care and pharmaceutical provision, facilitating a digital portal that connects patients with medical professionals and essential medications. Pomdoctor's operations largely encompass both a virtual hospital model and a comprehensive pharmaceutical supply chain, thus linking individual users, pharmacies, distributors, medical experts, and other healthcare stakeholders. This enterprise was established in 2010 and is headquartered in Guangzhou, China.

        CEO
        Zhenyang Shi
        Employees
        165
        Beta
        2.28

        Explore

        Frequently asked questions

        What is the intrinsic value of POMDOCTOR Ltd (POM)?

        InvestorsCraft does not currently publish an intrinsic value for POM. How the IC value is calculated.

        Is POM undervalued?

        InvestorsCraft does not publish an undervaluation signal for POM at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.